

# Pirh21 (7B9) Mouse mAb

Catalog # AP53504

## Product Information

Application	WB, IHC-P, IF, FC, ICC
Primary Accession	<a href="#">Q96PM5</a>
Reactivity	Rat, Human
Host	Mouse
Clonality	Monoclonal Antibody
Isotype	IgG1
Conjugate	Unconjugated
Immunogen	Purified recombinant fragment of human Pirh2 expressed in E. Coli.
Purification	Ascitic Fluid
Calculated MW	30110

## Additional Information

Gene ID	25898
Other Names	ARNIP; CHIMP; RNF199; RCHY1
Dilution	WB~~1:1000 IHC-P~~N/A IF~~1:50~200 FC~~1:10~50 ICC~~N/A
Format	Liquid in Purified antibody in PBS with 0.05% sodium azide.
Storage	Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.


## Protein Information

Name	RCHY1
Function	E3 ubiquitin-protein ligase that mediates ubiquitination of target proteins, including p53/TP53, TP73, HDAC1 and CDKN1B (PubMed: <a href="#">16914734</a> , PubMed: <a href="#">17721809</a> , PubMed: <a href="#">18006823</a> , PubMed: <a href="#">19043414</a> , PubMed: <a href="#">19483087</a> , PubMed: <a href="#">21994467</a> ). Mediates ubiquitination and degradation of p53/TP53; preferentially acts on tetrameric p53/TP53 (PubMed: <a href="#">19043414</a> , PubMed: <a href="#">19483087</a> ). Catalyzes monoubiquitinates the translesion DNA polymerase POLH (PubMed: <a href="#">21791603</a> ). Involved in the ribosome-associated quality control (RQC) pathway, which mediates the extraction of incompletely synthesized nascent chains from stalled ribosomes: RCHY1 acts downstream of NEMF and recognizes CAT tails associated with stalled nascent chains, leading to their ubiquitination and degradation (PubMed: <a href="#">33909987</a> ).
Cellular Location	Nucleus. Nucleus speckle. Cytoplasm


## Background

Swiss-Prot Acc.Q96PM5.Pirh 2 (P53 induced RING-H2 protein), also known as RCHY1, it forms dimers through its N- and C-terminus in cells. The Pirh2 has ubiquitin-protein ligase activity and it binds with p53 and promotes the ubiquitin-mediated proteosomal degradation of p53. The Pirh2 is oncogenic because loss of p53 function contributes directly to malignant tumor development. Pirh2 expression decreases the level of p53, and a decrease of endogenous Pirh2 expression increases p53 levels. Pirh2 is therefore considered, together with MDM2, to act as a negative regulator of p53 function.


## Images



Western blot detection of RCHY1 in Jurkat and MCF7 cell lysates using RCHY1 mouse mAb (1:1000 diluted). Predicted band size: 30 kDa. Observed band size: 60 kDa.




Immunofluorescence analysis of HeLa cells using Pirh2 mouse mAb (green). Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.



Flow cytometric analysis of PC-12 cells using anti-Pirh2 mAb (blue) and negative control (red).

Immunohistochemical analysis of paraffin-embedded human Tonsil tissues using anti-Pirh2 mouse mAb



Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.